Jefferies Financial Group Inc. Invests $26.75 Million in Kenvue Inc. $KVUE

Jefferies Financial Group Inc. bought a new position in shares of Kenvue Inc. (NYSE:KVUE) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,400,048 shares of the company’s stock, valued at approximately $26,755,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Public Employees Retirement System of Ohio purchased a new stake in Kenvue during the 2nd quarter worth about $10,328,000. One68 Global Capital LLC purchased a new position in shares of Kenvue in the 2nd quarter valued at about $283,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in shares of Kenvue in the 2nd quarter valued at about $82,000. Transamerica Financial Advisors LLC acquired a new stake in shares of Kenvue during the 2nd quarter worth about $272,000. Finally, Corient Private Wealth LP acquired a new stake in shares of Kenvue during the 2nd quarter worth about $9,627,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of NYSE KVUE opened at $19.20 on Friday. The stock has a market cap of $36.87 billion, a P/E ratio of 22.06, a P/E/G ratio of 1.38 and a beta of 0.47. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $20.82. The stock has a 50 day moving average of $19.14 and a two-hundred day moving average of $18.24. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the business posted $0.29 earnings per share. On average, research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th were given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend was Wednesday, August 12th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is 96.55%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KVUE. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Barclays raised their price objective on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. UBS Group reduced their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.